Reuters logo
FDA advisers vote against Delcath's cancer therapy
May 2, 2013 / 8:51 PM / 4 years ago

FDA advisers vote against Delcath's cancer therapy

May 2 (Reuters) - A panel of advisers to the U.S. health regulator said that risks outweighed the benefits in Delcath Systems Inc’s cancer therapy for a rare form of eye cancer that spreads to the liver.

The panel of independent experts voted 16-0 against the drug/device combination.

The drug-device combination product consists of a chemotherapy drug, melphalan hydrochloride, and a device known as the Delcath Hepatic Delivery System. The two are combined in a single package known as the Melblez Kit.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below